Recent Finacing
Recent Raise
ContraFect develops monoclonal antibodies and lysins to treat drug-resistant bacterial and viral infections, targeting conserved pathogen regions and pursuing antibody-plus-lysin combination therapies against MRSA, Pseudomonas, and influenza.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
